Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

समान संसाधन

• Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
  द्वारा: Cho, Kyu Yong, और अन्य
  प्रकाशित: (2018)
• Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
  द्वारा: Chiba, Koki, और अन्य
  प्रकाशित: (2020)
• Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
  द्वारा: Nakamura, Akinobu, और अन्य
  प्रकाशित: (2020)
• Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
  द्वारा: Miyoshi, Hideaki, और अन्य
  प्रकाशित: (2019)
• Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
  द्वारा: Miyoshi, Arina, और अन्य
  प्रकाशित: (2020)